Cardiol Therapeutics (CRDL) Corporate presentation summary

Strategic focus and pipeline

• Focused on anti-inflammatory and anti-fibrotic therapies for heart diseases, targeting underserved conditions such as recurrent pericarditis, acute myocarditis, and heart failure.

• Lead candidate CardiolRx™ is an oral cannabidiol solution in Phase II trials for rare heart diseases, with FDA orphan drug designation for pericarditis and eligibility for acute myocarditis.

• CRD-38, a novel subcutaneous cannabidiol formulation, is being developed for heart failure, with IND-enabling studies underway.

• Broad intellectual property portfolio supports exclusivity in rare disease markets, with 7–10 years of marketing exclusivity possible.

• Strong financial position, debt-free, and capitalized to achieve milestones into 2026.

Clinical programs and trial data

• MAVERIC-Pilot Phase II study for recurrent pericarditis showed CardiolRx™ reduced pain (NRS -3.7) and normalized CRP in 80% of symptomatic patients at 8 weeks.

• 89% of patients progressed to the extension period, indicating good tolerability.

• ARCHER Phase II trial for acute myocarditis is a double-blind, placebo-controlled study with 100 patients across five countries, focusing on myocardial recovery and safety.

• Preclinical data show CardiolRx™ and CRD-38 inhibit inflammatory pathways and reduce cardiac fibrosis and remodeling.

• CRD-38 demonstrated prevention of weight gain, inflammation, and cardiac remodeling in heart failure models.

Market need and opportunity

• Recurrent pericarditis and acute myocarditis have significant unmet needs, with limited approved therapies and high recurrence or complication rates.

• CardiolRx™ offers a potential oral, non-immunosuppressant alternative for patients resistant or intolerant to current therapies.

• Heart failure affects over 6 million in the US, with high mortality and economic burden; CRD-38 targets both HFrEF and HFpEF subtypes.

• Cannabidiol-based therapies may address inflammation and fibrosis, key drivers in these cardiac conditions.